Liraglutide vs Dulaglutide
## Overview
Liraglutide (Victoza/Saxenda) is once-daily; dulaglutide (Trulicity) is once-weekly. Both are GLP-1 receptor agonists with cardiovascular outcome trial evidence. Dulaglutide's once-weekly dosing provides a meaningful adherence advantage.
## Mechanism of Action
Both activate GLP-1 receptors. Liraglutide's 13-hour half-life requires daily dosing; dulaglutide's Fc fusion and structural modifications allow weekly dosing.
## Pharmacokinetics
Liraglutide: once daily, half-life ~13 h. Dulaglutide: once weekly, half-life ~4.7 days. Dulaglutide's longer half-life minimizes peak-to-trough fluctuations in plasma levels.
## Clinical Evidence
LEADER (liraglutide): 13% MACE reduction in T2DM with high CV risk — landmark trial establishing cardiovascular benefit of GLP-1 RAs. REWIND (dulaglutide): 12% MACE reduction in T2DM, including patients with lower baseline CV risk (primary prevention population included). Both are FDA-approved for CV risk reduction.
## Adherence
Once-weekly dulaglutide has a clear adherence advantage over once-daily liraglutide, with studies showing higher medication persistence. Patient satisfaction is generally higher with once-weekly dosing.
## Key Takeaways
- Dulaglutide: once weekly, comparable efficacy, similar CV benefit
- Liraglutide: once daily, first GLP-1 RA with CV outcome data, also approved for obesity (3 mg)
- Adherence advantage favors dulaglutide
الخلاصة
Dulaglutide is generally preferred over liraglutide for T2DM management due to once-weekly dosing improving adherence, with equivalent or comparable efficacy and CV benefit. Liraglutide is preferred when obesity treatment (Saxenda formulation at 3 mg) is the primary indication.